Visonac® data were presented at the Euro PDT congress in Barcelona February 13th

Data from the Visonac® Phase IIb study were presented by Professor Ann-Marie Wennberg at the 15th Annual Euro PDT congress in Barcelona.

The study included 153 patients enrolled at 15 office-based dermatology practices and hospitals in the US.  In patients treated with Visonac, a statistically significant reduction in inflammatory acne lesions of 43.8% was achieved compared to 26.6% in the control group (p=0.003). Visonac® also demonstrated improvement in overall acne severity in a significant percentage of patients as compared to control, 44.0%  versus 26.4% (p=0.013), respectively. Visonac was well tolerated and no serious adverse events were reported in the study.

Link to congress program and abstract C39, page 52

Banner PDT Congress 2016 Barcelona